各位老师和同学：
大家好，2026年6月15日（星期一），化学生物学与生物技术学院邀请了Scripps研究所化学系教授，美国国家科学院院士、美国艺术与科学院院士、美国国家医学院院士、美国国家发明家科学院院士到访我院并进行基于活性的蛋白组学分析——全局视角下的药物靶点与配体发现的讲座，欢迎大家参加！
6月15日上午9:00–11:50将于莲花山公园进行户外学术交流活动，欢迎感兴趣的PI届时参与；同日中午12:00–13:00进行学生午餐交流会，旨在促进学生与教授之间的深度学术交流。有意参加的学生请发送邮件至2536199055@pku.edu.cn报名，名额按报名先后顺序确定。
嘉 宾：Benjamin F. Cravatt, Ph.D.
嘉宾单位：The Scripps Research Institute
主 题：Activity-based protein profiling——target and ligand discovery on a global scale
时 间：2026年6月15日（星期一） 13:30-15:00
地 点：C105
邀 请 人：高晋君
讲座摘要：
Advances in DNA sequencing have greatly increased our understanding of the genetic basis of human disease. However, many of human genes encode proteins that remain uncharacterized and lack selective small-molecule probes. To address these problems, we have introduced activity-based protein profiling (ABPP), a chemical proteomic technology that globally profiles the functional state and small molecule interactions of proteins in native biological systems. In this lecture, I will describe the application of ABPP to generate covalent small molecule interaction (or ligandability) maps of human cells and how this information can guide the discovery of first-in-class chemical probes and drug candidates for disease-relevant proteins. Key themes will include: 1) the importance of assaying proteins in endogenous environments to realize their full small molecule interaction potential; 2) the capacity of covalent chemistry coupled with ABPP to extend the druggability of the proteome to reach historically challenging target families like adaptor/scaffolding proteins and DNA/RNA-binding proteins; and 3) the remarkably diverse ways that allosteric small molecules can regulate protein function in cells.
嘉宾简介：
Dr. Cravatt is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing innovative chemical technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is co-founder of several biotechnology companies, including Activx Biosciences, Abide Therapeutics, Vividion Therapeutics, and Belharra Therapeutics.（Focused on chemical proteomics and drug discovery for undruggable targets, Vividion Therapeutics was strategically acquired by Bayer AG in 2021.）Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, the ASBMB Merck Award, the Wolf Prize in Chemistry, the Heinrich Wieland Prize, the Tetrahedron Award for Creativity in Bioorganic and Medicinal Chemistry, The NAS Award in Chemical Science, and memberships in the National Academies of Inventors, Arts and Sciences, Medicine, and Sciences.
请注意： 本次讲座需要化学及生物方向学生签到！
